Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Shares Outstanding (Weighted Average): 2019-2025

Historic Shares Outstanding (Weighted Average) for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to $191.2 million.

  • BridgeBio Pharma's Shares Outstanding (Weighted Average) rose 1.67% to $191.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $191.2 million, marking a year-over-year increase of 1.67%. This contributed to the annual value of $189.0 million for FY2024, which is 8.64% up from last year.
  • As of Q3 2025, BridgeBio Pharma's Shares Outstanding (Weighted Average) stood at $191.2 million, which was up 0.68% from $189.9 million recorded in Q2 2025.
  • BridgeBio Pharma's 5-year Shares Outstanding (Weighted Average) high stood at $191.2 million for Q3 2025, and its period low was $147.2 million during Q4 2021.
  • Over the past 3 years, BridgeBio Pharma's median Shares Outstanding (Weighted Average) value was $187.1 million (recorded in 2024), while the average stood at $178.1 million.
  • Per our database at Business Quant, BridgeBio Pharma's Shares Outstanding (Weighted Average) climbed by 23.00% in 2021 and then decreased by 1.01% in 2022.
  • Over the past 5 years, BridgeBio Pharma's Shares Outstanding (Weighted Average) (Quarterly) stood at $147.2 million in 2021, then increased by 1.57% to $149.5 million in 2022, then climbed by 16.38% to $174.0 million in 2023, then climbed by 8.64% to $189.0 million in 2024, then increased by 1.67% to $191.2 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $191.2 million for Q3 2025, versus $189.9 million for Q2 2025 and $190.2 million for Q1 2025.